Proteinases in the pathogenesis of lymphangioleiomyomatosis lung disease: nibbling or chewing up the lung?

Yael Aschner,Gregory P. Downey

DOI: https://doi.org/10.1183/13993003.00405-2022

IF: 24.3

2022-04-01

European Respiratory Journal

Abstract:Lymphangioleiomyomatosis (LAM) is a slowly progressive, low-grade neoplasm predominantly affecting women that originates from tuberous sclerosis complex (TSC)-deficient cells of mesenchymal lineage ("LAM cells") in the uterus or pelvis [1, 2]. These LAM cells metastasise through the lymphatics to the abdominal and retroperitoneal lymph nodes, kidneys and lung [1–5]. LAM cells have loss-of-function mutations in both alleles of either TSC1 or TSC2 that function to inhibit the mechanistic target of rapamycin complex 1 (mTORC1). In the absence of tonic inhibition, the mTORC1 pathway is active and drives proliferation and invasion of LAM cells. Drugs such as sirolimus (rapamycin) and everolimus, that inhibit mTORC1, impede LAM cell growth and invasiveness and are clinically effective in slowing the progression of LAM disease [6–8], although this effect is reversible, necessitating continued treatment with medication. There is a subset of patients who progress despite treatment and/or are unable to tolerate the drugs. At present, other than monitoring of lung function tests [9], serum levels of vascular endothelial growth factor D [10], and cyst progression by computed tomography, all of which are lagging indicators of microscopic disease progression, there is no clinically useful way to monitor disease activity/progression and response to therapy.

respiratory system